TICKERNERD
Menu
TBPHTBPHHealthcare · Biotechnology

TBPH Stock Forecast: Theravance Biopharma, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$17
+0.38% on the day

The 5 Wall Street analysts covering Theravance Biopharma, Inc. hold a median 12-month price target of $17 — -0.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 22 Aug 2026 — inside the top quartile. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$883.1M
Ticker Nerd rank
89 / 100
Median analyst target
$17
Analysts covering
5
Total return, dividends reinvested
1W
+0.3%
1M
+1.0%
YTD
−9.1%
1Y
+24.6%
From 52W high
−18.0%
From 52W low
+25.4%
$14
$21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TBPH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Theravance Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
89 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Quality
94
Growth
90
Volatility
90
Momentum
73
Revisions
55
Size
47
Accruals
38
Issuance
34

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (34): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TBPH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TBPH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$14$16$18$20Oct 25Jan 26Apr 26Jul 26TBPHHigh $19Median $17Low $17

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
0 Buy5 Hold0 Sell
Low $17Median $17High $19

The green dot is the last close — the median target sits −0.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 July 2026HC Wainwright & Co.DowngradeNeutral$15 → $17
29 June 2026BTIGDowngradeNeutral—
29 June 2026Jones TradingDowngradeHold—
7 Apr 2026B. Riley SecuritiesMaintainsNeutral—
23 Mar 2026TD CowenMaintainsHold—
20 Mar 2026BTIGReiteratesBuy—
5 Mar 2026OppenheimerDowngradePerform—
4 Mar 2026B. Riley SecuritiesDowngradeNeutral—
4 Mar 2026HC Wainwright & Co.MaintainsBuy—
3 Mar 2026BTIGMaintainsBuy—
2 Mar 2026HC Wainwright & Co.MaintainsBuy—
3 Feb 2026BTIGReiteratesBuy—
3 Dec 2025OppenheimerInitiatesOutperform—
26 Nov 2025BTIGMaintainsBuy—
11 Nov 2025HC Wainwright & Co.MaintainsBuy—
12 Sept 2025B. Riley SecuritiesInitiatesBuy—
27 June 2025BTIGMaintainsBuy—
17 June 2025Jones TradingInitiatesBuy—
27 Feb 2025HC Wainwright & Co.ReiteratesBuy—
25 Feb 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TBPH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

TBPH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−94.1%
Analysts raising
0
Analysts cutting
0
Fundamentals

Theravance Biopharma, Inc. (TBPH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
16.4×

Cheaper than 45% of US stocks

Price / sales
8.5×

Cheaper than 17% of US stocks

Price / book
3.0×

Cheaper than 35% of US stocks

EV / EBITDA
48.1×

Cheaper than 5% of US stocks

Growth & margins
Revenue growth (YoY)
−20.9%

Higher than 11% of US stocks

Earnings growth (YoY)
15.0%

Higher than 53% of US stocks

Gross margin
—
Operating margin
8.9%

Higher than 62% of US stocks

Net margin
51.6%

Higher than 96% of US stocks

Returns & dividend
Return on equity
20.9%

Higher than 82% of US stocks

Return on assets
1.3%

Higher than 53% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TBPH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TBPHTheravance Biopharma, Inc.$883.1M
89
RIGLRigel Pharmaceuticals, Inc.$849.1M
79
FDMT4D Molecular Therapeutics, Inc.$874.5M
53
SGPSpyGlass Pharma, Inc.$883.2M
1
FTHFaeth Therapeutics, Inc.$824.9M
54
ACHVAchieve Life Sciences, Inc.$820.2M
29
AURAAura Biosciences, Inc.$806.4M
41

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Theravance Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TBPH news & analysis

TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders

Business Wire · 15 Aug 2026negative

Investor rights law firm Halper Sadeh LLC has opened an investigation into the sale of Theravance Biopharma to Zymeworks Inc. for $17.00 per share. The firm is examining whether Theravance and its board of directors violated their obligations in obtaining a fair price for shareholders, and is encouraging shareholders to learn about their rights.

Why it matters — TBPH watchers would care because the announcement raises questions about the fairness of the proposed acquisition price received by existing shareholders.

TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks

Zacks Investment Research · 11 Aug 2026neutral

Theravance Biopharma reported second-quarter earnings that matched analyst estimates. The company has also agreed to be acquired by Zymeworks in a $929 million deal, following cost cuts and the discontinuation of ampreloxetine.

Why it matters — TBPH watchers would care because the acquisition by Zymeworks marks a significant corporate change for the company following its earnings report and pipeline setback.

Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

PRNewsWire · 10 Aug 2026positive

Theravance Biopharma reported second quarter 2026 financial results, noting YUPELRI collaboration revenue rose 11% year-over-year to $20.7 million, a 35% reduction in operating expenses from restructuring and cost initiatives, a quarter-end cash balance of $388 million with no debt, and high confidence in achieving the $100 million 2026 milestone payment tied to TRELEGY net sales of approximately $1.0 billion. The company also reiterated that its previously announced acquisition by Zymeworks is expected to close in the second half of 2026.

Why it matters — TBPH watchers would care because the results highlight revenue growth, reduced expenses, a strong debt-free cash position, and progress toward the Zymeworks acquisition that resulted from the strategic review.

FAQ

Frequently asked questions about TBPH stock

What is the TBPH stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Theravance Biopharma, Inc. have a median 12-month price target of $17, with estimates ranging from $17 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TBPH stock a buy right now?

Of the 5 analysts covering Theravance Biopharma, Inc., 0 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Theravance Biopharma, Inc. 89 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TBPH?

As at 22 Aug 2026, Theravance Biopharma, Inc. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will TBPH stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies -0.1% from the last close, and Ticker Nerd's factor model ranks Theravance Biopharma, Inc. 89 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TBPH stock forecast for 2030?

No analyst covering Theravance Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TBPH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $19 over the next 12 months.

How has TBPH stock performed over the past year?

Theravance Biopharma, Inc. returned +24.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Theravance Biopharma, Inc. do?

Theravance Biopharma is a biopharmaceutical company focused on discovering, developing, and commercializing small-molecule medicines targeting respiratory disease, inflammatory and immunology conditions, and rare disorders. The company's flagship product, YUPELRI (revefenacin), is an FDA-approved once-daily, nebulized long-acting muscarinic antagonist for chronic obstructive pulmonary disease (COPD) maintenance treatment.

What is the latest news on TBPH?

The most recent item we track (Business Wire, 15 Aug 2026): "TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders". Investor rights law firm Halper Sadeh LLC has opened an investigation into the sale of Theravance Biopharma to Zymeworks Inc. for $17.00 per share. The firm is examining whether Theravance and its board of directors violated their obligations in obtaining a fair price for shareholders, and is encouraging shareholders to learn about their rights.

Company

About Theravance Biopharma, Inc.

Theravance Biopharma is a biopharmaceutical company focused on discovering, developing, and commercializing small-molecule medicines targeting respiratory disease, inflammatory and immunology conditions, and rare disorders. The company's flagship product, YUPELRI (revefenacin), is an FDA-approved once-daily, nebulized long-acting muscarinic antagonist for chronic obstructive pulmonary disease (COPD) maintenance treatment. Beyond its established respiratory franchise, Theravance Biopharma maintains a diversified clinical pipeline including ampreloxetine, a norepinephrine reuptake inhibitor in late-stage development for symptomatic neurogenic orthostatic hypotension, and a gut-selective pan-JAK inhibitor being evaluated for inflammatory bowel diseases. The company leverages internal research capabilities alongside strategic partnerships and collaborations to advance its candidates through clinical and regulatory milestones. Headquartered in South San Francisco, California, with corporate offices in Dublin, Ireland, Theravance Biopharma operates research facilities in the Bay Area supporting its global clinical programs and commercialization efforts.

CEO Mr. Rick E. Winningham M.B.A. · 90 employees · United States · https://www.theravance.com